Clear Search

Showing 2 results for “GC” published 2025.

November 2025

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China

Lancet 2025 Doi:10.1016/S0140-6736(25)01671-X Epub ahead of print

Gao et al. report that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and may address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost. Authors evaluated the safety, tolerability, and efficacy of allogeneic CD19 CAR NK-cell therapy in patients with relapsed or refractory SLE.

more…

July 2025

Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Arthritis & Rheumatology 2025; 0:1–7 doi: 10.1002/art.43209

Exposure to voclosporin for a median of 18 months was not associated with onset or progression of nephrotoxicity based on evaluation of histologic compartments and vascular lesions. Rovin et al. characterised the impact of voclosporin on kidney histology in patients with LN who had protocolized repeat kidney biopsies in the AURORA clinical trials.

more…